Technical Analysis for VYGR - Voyager Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 7.63 | 2.83% | 0.21 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 2.83% | |
| Wide Bands | Range Expansion | 2.83% | |
| Gapped Down | Weakness | 2.83% | |
| Oversold Stochastic | Weakness | 2.83% | |
| Narrow Range Bar | Range Contraction | 0.79% | |
| Wide Bands | Range Expansion | 0.79% | |
| Oversold Stochastic | Weakness | 0.79% | |
| Narrow Range Bar | Range Contraction | -0.26% | |
| Wide Bands | Range Expansion | -0.26% | |
| Oversold Stochastic | Weakness | -0.26% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 2 hours ago |
| Up 3% | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| Up 2% | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/07/2024
Voyager Therapeutics, Inc. Description
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system (CNS). The company focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease; and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich's ataxia, and VY-HTT01 for Huntington's disease, as well as VY-SMN101 for neuromuscular disease. The company has strategic collaborations with Genzyme Corporation and the University of Massachusetts Medical School. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Genetics Gene Therapy Parkinson's Disease Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Huntington's Disease Genzyme Monogenic Ataxia Friedreich's Ataxia Neuromuscular Disease Severe Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.3398 |
| 52 Week Low | 6.06 |
| Average Volume | 705,034 |
| 200-Day Moving Average | 8.23 |
| 50-Day Moving Average | 8.76 |
| 20-Day Moving Average | 8.55 |
| 10-Day Moving Average | 7.77 |
| Average True Range | 0.43 |
| RSI (14) | 34.21 |
| ADX | 25.0 |
| +DI | 17.17 |
| -DI | 32.80 |
| Chandelier Exit (Long, 3 ATRs) | 9.38 |
| Chandelier Exit (Short, 3 ATRs) | 8.54 |
| Upper Bollinger Bands | 10.33 |
| Lower Bollinger Band | 6.77 |
| Percent B (%b) | 0.18 |
| BandWidth | 41.66 |
| MACD Line | -0.45 |
| MACD Signal Line | -0.31 |
| MACD Histogram | -0.1395 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.81 | ||||
| Resistance 3 (R3) | 7.80 | 7.66 | 7.75 | ||
| Resistance 2 (R2) | 7.66 | 7.56 | 7.67 | 7.72 | |
| Resistance 1 (R1) | 7.54 | 7.50 | 7.60 | 7.55 | 7.70 |
| Pivot Point | 7.40 | 7.40 | 7.43 | 7.41 | 7.40 |
| Support 1 (S1) | 7.28 | 7.30 | 7.34 | 7.29 | 7.14 |
| Support 2 (S2) | 7.14 | 7.24 | 7.15 | 7.12 | |
| Support 3 (S3) | 7.02 | 7.14 | 7.10 | ||
| Support 4 (S4) | 7.03 |
